IL289457A - Methods of treating hiv in pediatric patients with rilpivirine - Google Patents

Methods of treating hiv in pediatric patients with rilpivirine

Info

Publication number
IL289457A
IL289457A IL289457A IL28945721A IL289457A IL 289457 A IL289457 A IL 289457A IL 289457 A IL289457 A IL 289457A IL 28945721 A IL28945721 A IL 28945721A IL 289457 A IL289457 A IL 289457A
Authority
IL
Israel
Prior art keywords
rilfivirine
methods
pediatric patients
treating hiv
hiv
Prior art date
Application number
IL289457A
Other languages
English (en)
Hebrew (he)
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of IL289457A publication Critical patent/IL289457A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL289457A 2019-07-03 2021-12-28 Methods of treating hiv in pediatric patients with rilpivirine IL289457A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962870413P 2019-07-03 2019-07-03
US16/919,677 US20210000823A1 (en) 2019-07-03 2020-07-02 Methods of treating hiv
PCT/EP2020/068913 WO2021001568A1 (en) 2019-07-03 2020-07-03 Methods of treating hiv in pediatric patients with rilpivirine

Publications (1)

Publication Number Publication Date
IL289457A true IL289457A (en) 2022-02-01

Family

ID=71579550

Family Applications (1)

Application Number Title Priority Date Filing Date
IL289457A IL289457A (en) 2019-07-03 2021-12-28 Methods of treating hiv in pediatric patients with rilpivirine

Country Status (14)

Country Link
US (3) US20210000823A1 (enExample)
EP (2) EP3993799A1 (enExample)
JP (4) JP2022538338A (enExample)
KR (2) KR20220028049A (enExample)
CN (2) CN114126655A (enExample)
AU (2) AU2020300818A1 (enExample)
BR (2) BR112021026916A2 (enExample)
CA (1) CA3144307A1 (enExample)
IL (1) IL289457A (enExample)
JO (1) JOP20210347A1 (enExample)
MA (2) MA56449A (enExample)
MX (2) MX2022000060A (enExample)
PH (1) PH12021553288A1 (enExample)
WO (2) WO2021001508A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3429B1 (ar) * 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
AR065720A1 (es) * 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
NZ610729A (en) * 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
CA2921336A1 (en) * 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
EP4233846B1 (en) * 2015-06-30 2024-12-04 Gilead Sciences, Inc. Pharmaceutical formulations
MA46563B1 (fr) * 2016-10-24 2024-01-31 Janssen Sciences Ireland Unlimited Co Compositions dispersibles
RU2755710C2 (ru) * 2017-06-30 2021-09-20 Вайв Хелткер Компани Комбинация, ее применение и способы лечения с использованием указанной комбинации
MA56449A (fr) * 2019-07-03 2022-05-11 Janssen Sciences Ireland Unlimited Co Procédés de traitement du vih chez des patients pédiatriques par la rilpivirine

Also Published As

Publication number Publication date
WO2021001568A1 (en) 2021-01-07
MA56449A (fr) 2022-05-11
MX2021015627A (es) 2022-04-25
CN114126655A (zh) 2022-03-01
JP2026097814A (ja) 2026-06-16
BR112021026916A2 (pt) 2022-05-10
CN114080223A (zh) 2022-02-22
CA3144307A1 (en) 2021-01-07
EP3993799A1 (en) 2022-05-11
JP2022538449A (ja) 2022-09-02
JP2022538338A (ja) 2022-09-01
MX2022000060A (es) 2022-04-18
JP2026097815A (ja) 2026-06-16
KR20220028048A (ko) 2022-03-08
US20220313693A1 (en) 2022-10-06
CA3144534A1 (en) 2021-01-07
KR20220028049A (ko) 2022-03-08
AU2020300818A1 (en) 2022-03-03
BR112021026739A2 (pt) 2022-04-26
EP3993800A1 (en) 2022-05-11
US20240139186A1 (en) 2024-05-02
PH12021553288A1 (en) 2022-08-01
US20210000823A1 (en) 2021-01-07
WO2021001508A1 (en) 2021-01-07
MA56453A (fr) 2022-05-11
JOP20210347A1 (ar) 2023-01-30
AU2020300033A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
IL281445A (en) Therapeutic nanoparticles and methods for their use
IL276494A (en) Niraprib formulations for children and methods for treating children
GB201907283D0 (en) Use of cannabidiol in the treatment of epileptic spams
IL264301A (en) Treatment of Fabry disease in ert-naive and ert-experienced patients
PT3087178T (pt) Método para produzir oxalato oxidases que têm atividade ótica próxima ao ph fisiológico e utilização de tais oxalato oxidases recombinantes no tratamento de doenças relacionadas com oxalato
IL272893A (en) Methods for increasing and/or stabilizing cardiac functions in patients with Fabry disease
IL286334B1 (en) Modified microRNAs and their use in cancer treatment
IL268210A (en) Use of gaboxadol in the treatment of tinnitus
ZA201804950B (en) Indolinones compounds and their use in the treatment of fibrotic diseases
EP3344632A4 (en) Heterocyclic pyrimidine compounds and their use in the treatment of medical disorders
GB201710822D0 (en) Methods and medical uses relating to the treatment of hypoglycaemia
SG11202000423XA (en) Treatment of fabry disease in ert-naïve and ert-experienced patients
ZA201904967B (en) Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer
ZA201706012B (en) Patient incontinence and lifting pad
IL280453B2 (en) History of benzenesulfonamide-phenyl-alkyloxy-alkyl acids and their use in therapy.
GB201519557D0 (en) Compounds for use in the treatment of telomere related diseases and/or telomere related medical conditions
EP3644753A4 (en) METHODS FOR MAINTAINING AND IMPROVING RENAL FUNCTION IN PATIENTS WITH RENAL DISEASE AND STANDARD TREATMENT THERAPY
PT3937948T (pt) Fitoecdisonas e seus derivados para utilização no tratamento de doenças neuromusculares
HK40071761A (en) Methods of treating hiv in pediatric patients with rilpivirine
HK40071757A (en) Methods of treating hiv in pediatric patients with rilpivirine
PH12021553288A1 (en) Methods of treating hiv in pediatric patients with rilpivirine
EP3661494B8 (en) Use of tasimelteon for the treatment of affective disorders in majority black african patients
LT4225291T (lt) Cholangiopatijų gydymas seladelparu
HK40029560A (en) Methods and medical uses relating to the treatment of hypoglycaemia
GB201612792D0 (en) Theraputic use of oleoylethano-lamide in brain cancer treatment